Antimicrobial Susceptibility Testing: Advanced Course
|
|
- Alyson Harmon
- 6 years ago
- Views:
Transcription
1 Antimicrobial Susceptibility Testing: Advanced Course
2 Cascade Reporting
3 Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to test & report is a decision best made by each clinical laboratory in consultation with: Infectious disease practitioners Pharmacy Pharmacy & Therapeutics committee Infection Control committee Considerations of antimicrobials include: clinical efficacy prevalence of resistance (& minimizing the emergence of resistance) cost FDA clinical indications for use current consensus for first-choice and alternative drugs tests of selected agents may be useful for infection control purposes
4 Test/Report Groups. Group A are considered appropriate for inclusion in a routine, primary testing panel, as well as for routine reporting of results for the specific organism groups. 2. Group B includes antimicrobial agents that may warrant primary testing but they may be reported only selectively, such as when the organism is resistant to agents of the same antimicrobial class, as in Group A. Other indications for reporting the result might include a selected specimen source (eg, a third-generation cephalosporin for enteric bacilli from cerebrospinal fluid or trimethoprim-sulfamethoxazole for urinary tract isolates); a polymicrobial infection; infections involving multiple sites; cases of patient allergy, intolerance, or failure to respond to an agent in Group A; or for purposes of infection control.. Group C includes alternative or supplemental antimicrobial agents that may require testing in those institutions that harbor endemic or epidemic strains resistant to several of the primary drugs (especially in the same class, eg, -lactams); for treatment of patients allergic to primary drugs; for treatment of unusual organisms (eg, chloramphenicol for extraintestinal isolates of Salmonella spp.); or for reporting to infection control as an epidemiological aid.. Group U ( urine ) includes antimicrobial agents (eg, nitrofurantoin and certain quinolones) that are used only or primarily for treating urinary tract infections. These agents should not be routinely reported against pathogens recovered from other sites of infection. Other agents with broader indications may be included in Group U for specific urinary pathogens (eg, P. aeruginosa and ofloxacin). 5. Group O ( other ) includes antimicrobial agents that have a clinical indication for the organism group, but are generally not candidates for routine testing and reporting in the United States. 6. Group Inv. ( investigational ) includes antimicrobial agents that are investigational for the organism group and have not yet been approved by the FDA for use in the United States.
5 Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Group A appropriate for inclusion in a routine, primary testing panel, appropriate for routine reporting of results for the specific organism groups
6 GROUP A PRIMARY TEST AND REPORT Cascade Reporting Table A. Enterobacteriaceae Pseudomonas aeruginosa Staphylococcus spp. Ampicillin d Ceftazidime Azithromycin b or clarithromycin b or erythromycin b Cefazolin e Gentamicin Tobramycin Gentamicin Tobramycin Piperacillin Clindamycin b *, Oxacillin i,k Cefoxitin i,k (surrogate test for oxacillin) Penicillin i Trimethoprimsulfamethoxazole Enterococcus spp. m Ampicillin n Penicillin o
7 GROUP A PRIMARY TEST AND REPORT Report routinely Cascade Reporting Table A. Enterobacteriaceae Pseudomonas aeruginosa Staphylococcus spp. Ampicillin d Ceftazidime Azithromycin b or clarithromycin b or erythromycin b Cefazolin e Gentamicin Tobramycin Gentamicin Tobramycin Piperacillin/ tazobactam Clindamycin b *, Oxacillin i,k Cefoxitin i,k (surrogate test for oxacillin) Penicillin i Trimethoprimsulfamethoxazole Enterococcus spp. m Ampicillin n Penicillin o
8 Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting 2. Group B includes antimicrobial agents that may warrant primary testing but they may be reported only selectively, such as when the organism is resistant to agents of the same antimicrobial class in Group A. Other indications for reporting: selected specimen source (urine), failure to respond to an agent in Group A, or for purposes of infection control
9 GROUP B PRIMARY TEST REPORT SELECTIVELY Table A. Cascade Reporting Enterobacteriaceae Amikacin Amikacin Ceftaroline h *Daptomycin j *Daptomycin j Aztreonam Linezolid Linezolid Amoxicillin-clavulanate Ampicillin-sulbactam Piperacillin-tazobactam Ticarcillin-clavulanate Cefuroxime Cefepime Pseudomonas aeruginosa Staphylococcus spp. Doxycycline Minocycline b Tetracycline a Enterococcus spp. m Vancomycin Cefepime Cefotetan Cefoxitin Cefotaxime d,e or ceftriaxone d,e Ciprofloxacin d Levofloxacin d Doripenem Ertapenem Imipenem Meropenem Piperacillin Trimethoprim-sulfamethoxazole d Ciprofloxacin Levofloxacin Doripenem Imipenem Meropenem Piperacillin-tazobactam Ticarcillin *, Vancomycin Rifampin g
10 GROUP B PRIMARY TEST REPORT SELECTIVELY Table A. Cascade Reporting Report routinely Test routinely *Cascade reported Enterobacteriaceae Amikacin* Amikacin* Ceftaroline h *Daptomycin j * *Daptomycin j * Aztreonam Linezolid* Linezolid* Amoxicillin-clavulanate* Ampicillin-sulbactam Piperacillin-tazobactam Ticarcillin-clavulanate Cefuroxime Cefepime Pseudomonas aeruginosa Staphylococcus spp. Doxycycline* Minocycline b Tetracycline a Enterococcus spp. m Vancomycin Cefepime* Cefotetan Cefoxitin Cefotaxime d,e or ceftriaxone d,e * Ciprofloxacin d Levofloxacin d Doripenem Ertapenem* Imipenem Meropenem* Piperacillin Trimethoprim-sulfamethoxazole d Ciprofloxacin Levofloxacin Doripenem Imipenem Meropenem Piperacillin-tazobactam Ticarcillin *, Vancomycin Rifampin g *
11 Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting. Group C includes alternative or supplemental antimicrobial agents that may require testing in those institutions that harbor endemic or epidemic strains resistant to several of the primary drugs, for treatment of patients allergic to primary drugs, for treatment of unusual organisms, or for reporting to infection control as an epidemiological aid
12 GROUP C SUPPLEMENTAL REPORT SELECTIVELY Table A. Cascade Reporting Enterobacteriaceae Aztreonam Ceftazidime Pseudomonas aeruginosa Staphylococcus spp. Chloramphenicol b Enterococcus spp. m Gentamicin (high-level resistance screen only) Ceftaroline Ciprofloxacin or levofloxacin or ofloxacin Moxifloxacin Streptomycin (high-level resistance screen only) Chloramphenicol b,d Gentamicin l Tetracycline a
13 GROUP C SUPPLEMENTAL REPORT SELECTIVELY Table A. Cascade Reporting Report routinely Test routinely Selectively reported Enterobacteriaceae Aztreonam Ceftazidime* Pseudomonas aeruginosa Staphylococcus spp. Chloramphenicol b Enterococcus spp. m Gentamicin (high-level resistance screen only) Ceftaroline Ciprofloxacin or levofloxacin or ofloxacin Moxifloxacin Streptomycin (high-level resistance screen only) Chloramphenicol b,d Gentamicin l Tetracycline a *
14 Clindamycin Erythromycin Oxacillin Vancomycin Chloramphenicol Cefazolin Penicillin Ceftriaxone Moxifloxacin Tetracycline Ampicillin Linezolid SXT Levofloxacin Gent Synergy Cascade Reporting: GPC Non-urine/Non-CSF Staphylococcus species (V2) R 2, 5 Streptococcus pneumoniae: non-sterile sites (V2) 9 Streptococcus pneumoniae: sterile sites (V2) 9 Viridans Streptococcus (KB & E-test or Microscan) MIC Enterococcus spp (V2) 6 -strep (GAS, GBS, GCS, GGS) spp: sterile sites (KB) (2) S.agalactiae: from OB screens (KB) 0 MIC 8 7
15 Clindamycin Erythromycin Oxacillin Vancomycin Chloramphenicol Cefazolin Penicillin Ceftriaxone Moxifloxacin Tetracycline Ampicillin Linezolid SXT Levofloxacin Gent Synergy Cascade Reporting: GPC Non-urine/Non-CSF Staphylococcus species (V2) R 2, 5 Streptococcus pneumoniae: non-sterile sites (V2) 9 Streptococcus pneumoniae: sterile sites (V2) 9 Viridans Streptococcus (KB & E-test or Microscan) MIC Enterococcus spp (V2) 6 -strep (GAS, GBS, GCS, GGS) spp: sterile sites (KB) (2) S.agalactiae: from OB screens (KB) 0 MIC 8 7 R Routinely reported. Always report as resistant. If SDD, I or R, report antimicrobials touching arrowhead
16 Clindamycin Erythromycin Oxacillin Vancomycin Chloramphenicol Cefazolin Penicillin Ceftriaxone Moxifloxacin Tetracycline Ampicillin Linezolid SXT Levofloxacin Gent Synergy Cascade Reporting: GPC Non-urine/Non-CSF Staphylococcus species (V2) R 2, 5 Streptococcus pneumoniae: non-sterile sites (V2) 9 Streptococcus pneumoniae: sterile sites (V2) 9 Viridans Streptococcus (KB & E-test or Microscan) MIC Enterococcus spp (V2) 6 -strep (GAS, GBS, GCS, GGS) spp: sterile sites (KB) (2) S.agalactiae: from OB screens (KB) Perform D-test; Report Clinda-R if D-test positive. 2 If S. aureus and vanco MIC = 2, add comment code VANCO2 : Vancomycin MIC = 2 µg/ml. For isolates with a vancomycin minimum inhibitory concentration (MIC) of 2, the patient s clinical response should determine the continued use of vancomycin, independent of the MIC. 0 MIC 8 7
17 Clindamycin Erythromycin Oxacillin Vancomycin Chloramphenicol Cefazolin Penicillin Ceftriaxone Moxifloxacin Tetracycline Ampicillin Linezolid SXT Levofloxacin Gent Synergy Cascade Reporting: GPC Non-urine/Non-CSF Staphylococcus species (V2) R 2, 5 Streptococcus pneumoniae: non-sterile sites (V2) 9 Streptococcus pneumoniae: sterile sites (V2) 9 Viridans Streptococcus (KB & E-test or Microscan) MIC Enterococcus spp (V2) 6 -strep (GAS, GBS, GCS, GGS) spp: sterile sites (KB) (2) S.agalactiae: from OB screens (KB) 0 MIC 8 7 CF (Cystic Fibrosis) isolates only If MRSA, report chloramphenicol and linezolid. Report Cefazolin as resistant if Oxacillin is resistant. 5 If testing manually, use E-test (not KB).
18 Clindamycin Erythromycin Oxacillin Vancomycin Chloramphenicol Cefazolin Penicillin Ceftriaxone Moxifloxacin Tetracycline Ampicillin Linezolid SXT Levofloxacin Gent Synergy Cascade Reporting: GPC Non-urine/Non-CSF Staphylococcus species (V2) R 2, 5 Streptococcus pneumoniae: non-sterile sites (V2) 9 Streptococcus pneumoniae: sterile sites (V2) 9 Viridans Streptococcus (KB & E-test or Microscan) MIC Enterococcus spp (V2) 6 -strep (GAS, GBS, GCS, GGS) spp: sterile sites (KB) (2) S.agalactiae: from OB screens (KB) 6 If vancomycin-r E.casseliflavus or E.gallinarum, add comment NOTVRE to report. 7 Report Gentamicin synergy only for Blood isolates; Report as resistant when Ampicillin resistant & Vancomycin resistant regardless of test result. 8 Report only on VRE. 0 MIC 8 7
19 Clindamycin Erythromycin Oxacillin Vancomycin Chloramphenicol Cefazolin Penicillin Ceftriaxone Moxifloxacin Tetracycline Ampicillin Linezolid SXT Levofloxacin Gent Synergy Cascade Reporting: GPC Non-urine/Non-CSF Staphylococcus species (V2) R 2, 5 Streptococcus pneumoniae: non-sterile sites (V2) 9 Streptococcus pneumoniae: sterile sites (V2) 9 Viridans Streptococcus (KB & E-test or Microscan) MIC Enterococcus spp (V2) 6 -strep (GAS, GBS, GCS, GGS) spp: sterile sites (KB) (2) S.agalactiae: from OB screens (KB) 0 MIC Transcribe the Penicillin MIC result into both the Pen IV and Pen oral MIC fields in the LIS. 0 Do not report but add comment BETAS to report ( Beta-hemolytic streptococci are routinely susceptible to penicillins and cephalosporins. ) Report CTX (meningitis) and CTX (non-meningitis) results.
20 Clindamycin Erythromycin Oxacillin Vancomycin Chloramphenicol Cefazolin Penicillin Ceftriaxone Moxifloxacin Tetracycline Ampicillin Linezolid SXT Levofloxacin Gent Synergy Cascade Reporting: GPC Non-urine/Non-CSF Staphylococcus species (V2) R 2, 5 Streptococcus pneumoniae: non-sterile sites (V2) 9 Streptococcus pneumoniae: sterile sites (V2) 9 Viridans Streptococcus (KB & E-test or Microscan) MIC Enterococcus spp (V2) 6 -strep (GAS, GBS, GCS, GGS) spp: sterile sites (KB) (2) S.agalactiae: from OB screens (KB) 0 MIC For -hemolytic viridans strep (i.e., S.anginosis group) use the Viridans Streptococcus cascade. Report for S.aureus only. If Penicillin-S and Ceftriaxone-NS, restest and bring to rounds.
21 Oxacillin Vancomycin Cefazolin Penicillin Tetracycline Ampicillin Ciprofloxacin Nitrofurantoin Linezolid SXT Cascade Reporting: GPC Urine V2 Staphylococcus spp, 5 2 R 6 Enterococcus spp R Routinely reported. Always report as resistant.
22 Oxacillin Vancomycin Cefazolin Penicillin Tetracycline Ampicillin Ciprofloxacin Nitrofurantoin Linezolid SXT Cascade Reporting: GPC Urine V2 Staphylococcus spp, 5 2 R 6 Enterococcus spp If S. aureus and vanco MIC = 2, add comment code VANCO2 : Vancomycin MIC = 2 µg/ml. For isolates with a vancomycin minimum inhibitory concentration (MIC) of 2, the patient s clinical response should determine the continued use of vancomycin, independent of the MIC. 2 Report Cefazolin as R if Oxacillin is R, and report Cefazolin as S if Oxacillin is S.
23 Oxacillin Vancomycin Cefazolin Penicillin Tetracycline Ampicillin Ciprofloxacin Nitrofurantoin Linezolid SXT Cascade Reporting: GPC Urine V2 Staphylococcus spp, 5 2 R 6 Enterococcus spp If vancomycin-resistant E.casseliflavus or E.gallinarum, add comment NOTVRE to report. Report only on VRE. 5. If testing manually, use E-test (not KB). 6. Report on S. aureus only.
24 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R 8 8
25 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R 8 8 R Routinely reported. Always report as resistant. If SDD, I or R, report antimicrobials touching arrowhead.
26 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R 8 8 For Cipro susceptible Salmonella, test Nalidixic acid by KB. If Nalidixic Acid is S, report the Ciprofloxacin result. If Nalidixic Acid is I or R, report Ciprofloxacin and Nalidixic Acid and add the following comment to report: ( SALMFQ ) = Fluoroquinolone-susceptible strains of Salmonella that test non-susceptible to nalidixic acid may be associated with clinical failure or delayed response in fluoroquinolone-treated patients with extra intestinal salmonellosis. A consultation with an infectious disease practitioner is recommended.
27 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R Report only for urinary isolates. If Vitek result is I or R, perform an alternate method of testing due to Vitek limitation. If Ceftriaxone is S, I or R and Ceftazidime and/or Cefipime is non-s (SDD, I or R), then report Ceftriaxone, Ceftazidime, and Cefepime.
28 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R Only if Cefepime is non-s, continue cascade and report Ertapenem and Meropenem. 6 Perform an alternate method of testing for Pip/Tazo vs. Serratia marcescens due to a Vitek limitation. 7 If Ceftazidime is non-s or if Vitek flags the isolate as an ESBL, result the ESBL biochemical as Yes for E.coli, Klebsiella spp and P.mirabilis.
29 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R If Ceftriaxone is non-susceptible, confirm results. Bring to rounds if non-susceptibility is confirmed. 9 Due to a Vitek limitation, Ampicillin is not routinely reported for Pantoea spp. If Ampicillin is requested, test by KB and cascade to Amox/Clav if Ampicillin is resistant.
30 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R Even if not cascaded, if Ertapenem and/or Meropenem are non-susceptible, confirm by disk diffusion, including Imipenem. If non-susceptibility is confirmed, report Ertapenem, Meropenem and Imipenem and refer to Attachment 8 to see if the isolate meets the case definition for CRE.
31 Ampicillin Amox/Clav. Gentamicin Pip/Tazo Tobramycin Cefazolin Ceftriaxone Ertapenem 0 & Trimeth/Sulfa Ciprofloxacin Nalidixic Acid Cascade Reporting: Enterobacteriaceae non-csf V2 Amikacin Nitrofurantoin 2 Tetracycline 2 Ceftazidime 7 Cefepime 5 Meropenem 0 E. coli Pantoea spp. P. mirabilis Klebsiella spp Citrobacter koseri Citrobacter spp (except C. koseri) Enterobacter spp Hafnia alveii Serratia spp Morganella morganii Proteus vulgaris/penneri Providencia spp Salmonella spp Shigella spp n/a 9 R R R R R R R R R R 6 R R R R R R R 8 8. Even if it is not cascaded, if Amikacin is non-susceptible, report Gentamycin, Tobramycin and Amikacin.
32 Ceftriaxone ( rd gen) Gentamicin Tobramycin Amikacin Trimeth/Sulfa Ciprofloxacin Pip/Tazo Ceftazidime Cefepime Meropenem Levofloxacin Timentin Cascade Reporting: Non-Enterobacteriaceae non-csf V2 Pseudomonas aeruginosa 5 6 Pseudomonas spp () Other non-enteric bacilli () 5 Burkholderia cepacia Stenotrophomonas maltophilia Acinetobacter spp 2 2
33 Ceftriaxone ( rd gen) Gentamicin Tobramycin Amikacin Trimeth/Sulfa Ciprofloxacin Pip/Tazo Ceftazidime Cefepime Meropenem Levofloxacin Timentin Cascade Reporting: Non-Enterobacteriaceae non-csf V2 Pseudomonas aeruginosa 5 6 Pseudomonas spp () Other non-enteric bacilli () 5 Burkholderia cepacia Stenotrophomonas maltophilia Acinetobacter spp 2 2 Routinely reported. If I or R, report antimicrobials touching arrowhead.
34 Ceftriaxone ( rd gen) Gentamicin Tobramycin Amikacin Trimeth/Sulfa Ciprofloxacin Pip/Tazo Ceftazidime Cefepime Meropenem Levofloxacin Timentin Cascade Reporting: Non-Enterobacteriaceae non-csf V2 Pseudomonas aeruginosa 5 6 Pseudomonas spp () Other non-enteric bacilli () 5 Burkholderia cepacia Stenotrophomonas maltophilia Acinetobacter spp 2 2 Perform by manual MIC panel testing. 2 Amikacin must be tested by KB due to a Vitek-2 limitation; if you suspect the ID will be an Acinetobacter spp, set an AMK KB at the same time as you set up the AST panel. Also set PTZ KB as Vitek may not interpret results on Acinetobacter spp. other than A. baumannii. MIC testing only.
35 Ceftriaxone ( rd gen) Gentamicin Tobramycin Amikacin Trimeth/Sulfa Ciprofloxacin Pip/Tazo Ceftazidime Cefepime Meropenem Levofloxacin Timentin Cascade Reporting: Non-Enterobacteriaceae non-csf V2 Pseudomonas aeruginosa 5 6 Pseudomonas spp () Other non-enteric bacilli () 5 Burkholderia cepacia Stenotrophomonas maltophilia Acinetobacter spp 2 2 If Vitek result is resistant perform an alternate method of testing due to a Vitek limitation. 5 Report Amikacin if either Gentamicin or Tobramycin are non-s. 6 If Timentin is requested test by KB (not MIC panel).
36 Ampicillin Ceftriaxone Oxacillin Penicillin SXT Vancomycin Meropenem Cascade Reporting: GPC CSF Gram Positive Staphylococcus spp (V2) Streptococcus pneumoniae (V2) Viridans Streptococcus E-test E-test Enterococcus spp (V2), 2 Routinely reported. If Vancomycin MIC is > 2 for S. aureus, set up E-test for Vancomycin and bring to rounds if E-test MIC is > 2. If vanco MIC = 2, add comment code VANCO2 = Vancomycin MIC = 2 µg/ml. For isolates with a vancomycin minimum inhibitory concentration (MIC) of 2, the patient s clinical response should determine the continued use of vancomycin, independent of the MIC. 2 If testing manually, use E-test. Report CTX (meningitis) only and Penicillin (IV) only.
37 Amikacin Ampicillin Amox/Clav Ceftriaxone Ceftazidime Cefepime Gentamicin Pip/Tazo Meropenem Ertapenem SXT Tobramycin Cascade Reporting: GNR CSF Gram Negative E. coli (V2) P. Mirabilis Salmonella spp (V2) Shigella spp 2 All other enteric GNRs (V2) Non-enterics (V2) (non-fermenters) Routinely reported. If I or R, report antimicrobials touching arrowhead.. For E. coli, Klebsiella spp., and P. mirabilis: If Ceftazidime is non-s or if Vitek flags the isolate as ESBL, result ESBL biochem as Yes. 2. If Ceftriaxone is non-susceptible, confirm results. Bring to rounds if non-susceptibility is confirmed.. Even if not cascaded, if Ertapenem and/or Meropenem are confirmed as non-susceptible, report both.
38 Cascade Reporting SUMMARY: Use the CLSI M00 document as a guide. Decide with your ID, ID pharmacy, and IC clinicians what should be reported for your organism groups. What is routinely reported What is cascaded What is tested/reported only by special request Have clear guidance/training for your staff.
39 EXERCISE Develop a cascade reporting document (with footnotes!) for an inpatient population for the enterobacteriaceae using the CLSI M00-S2 along with the following directions from your Infectious Disease team: First line aminoglycoside is tobramycin Piperacillin/tazobactam reported out on all GNRs Cefepime should be reserved for resistant organisms Carbapenem of choice is imipenem, but should be reserved for resistant organisms Levofloxacin is used primarily, not ciprofloxacin Cefotaxime is the primary rd generation cephalosporin Include any special considerations for UTI organisms
40 DRUGS GN BUGs
2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationTABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11
Policy #MI\ANTI\v23 Page 1 of 3 Section: Antimicrobial Susceptibility Testing Subject Title: Table of Contents Manual Issued by: LABORATORY MANAGER Original Date: January 10, 2000 Approved by: Laboratory
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationUNDERSTANDING YOUR DATA: THE ANTIBIOGRAM
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationSMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationAntimicrobial Susceptibility Summary 2011
Antimicrobial Susceptibility Summary 2011 Clinical Microbiology Department of Pathology & Laboratory Medicine 45 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationAntimicrobial Susceptibility Summary 2012
Antimicrobial Susceptibility Summary 2012 Clinical Microbiology Department of Pathology & Laboratory Medicine 46 53 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationUNDERSTANDING THE ANTIBIOGRAM
UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationDetecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)
Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationSurveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler
Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationLeveraging the Lab and Microbiology Department to Optimize Stewardship
Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationANTIMICROBIAL RELATED LIS CANNED MESSAGES
Policy # MI\ANTI\04\v01 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Antimicrobial Related LIS Canned Issued by: LABORATORY MANAGER Original Date: November 21, 2005 Approved
More informationRecommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data
Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory
More informationPrinciples of Antibiotics Use & Spectrum of Some
Principles of Antibiotics Use & Spectrum of Some Rabee Adwan. MD Infectious Diseases Consultant (Pediatric and Adult) Head Of ID Unit and IPAC Committee- AL-Makassed Hospital-AlQuds Head of IPAC Committee
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationBritish Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method
More informationBritish Society for Antimicrobial Chemotherapy
British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationCUMULATIVE ANTIBIOGRAM
BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA
More informationUpdate on the CLSI Standards for Antimicrobial Susceptibility Testing: What s New with the Gram Positive Organisms?
2 0 1 3 CASES (with answers!) Update on the CLSI Standards for Antimicrobial Susceptibility Testing: What s New with the Gram Positive Organisms? Susan E. Sharp, Ph.D., DABMM, FAAM Director - Regional
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationAntimicrobial Resistance Trends in the Province of British Columbia
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationNon-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationPolicy # MI_AST Department of Microbiology. Page Quality Manual
Department of Microbiology Version: 2.0 CURRENT 1 of 160 Prepared by QA Committee Issued by: Laboratory Manager Revision Date: 2/26/2018 Approved by Laboratory Director: Annual Review Date: 5/1/2018 Microbiologist-in-Chief
More informationTaiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
More informationInterpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi
More informationAMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
More informationHUSRES Annual Report 2007 Martti Vaara.
HUSRES Annual Report 2007 Martti Vaara www.huslab.fi www.intra.hus.fi The basis of this HUSRES 2007 report is the HUSLAB/Whonet database 2007, which contains susceptibility data on about 182.000 bacteria
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationBSAC standardized disc susceptibility testing method (version 8)
Journal of Antimicrobial Chemotherapy (2009) 64, 454 489 doi:10.1093/jac/dkp244 Advance Access publication 8 July 2009 BSAC standardized disc susceptibility testing method (version 8) J. M. Andrews* for
More informationAntimicrobial Agents 101. SWACM 2011 Christopher Doern, Ph.D., D(ABMM)
Antimicrobial Agents 101 SWACM 2011 Christopher Doern, Ph.D., D(ABMM) β -Lactams Penicillins Cephalosporins Carbapenems Monobactams β -Lactamase Inhibitors Clavulanate Amox/Clav Ticar/Clav Sulbactam Amp/Sulb
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationMicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS
MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS LABORATORIES ON THE FRONT LINE From the National Action Plan for Combating Antibiotic Resistant
More informationA Multi-Laboratory Study of the BIOMIC Automated Well Reading Instrument versus
JCM Accepts, published online ahead of print on 13 March 2013 J. Clin. Microbiol. doi:10.1128/jcm.03088-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 A Multi-Laboratory
More informationInfectious Disease: Drug Resistance Pattern in New Mexico
Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?
More informationMichael Hombach*, Guido V. Bloemberg and Erik C. Böttger
J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationDr Neeraj Goel Sr. Consultant Department of Clinical Microbiology. Sir Ganga Ram Hospital
Dr Neeraj Goel Sr. Consultant Department of Clinical Microbiology Sir Ganga Ram Hospital Resistance profile of MDROs in ICU: Quinolone: 80% Amikacin: 75% Cefaperazone sulbactum: 79% Carbapenems: 79% Super
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department
More information